SuperworthImmunome price to sales ratio IMNM
Market value divided by revenue over the last twelve months, since 2024.
- Today, Oct 23, 2026
- n/m
- not in our data today
- Last meaningful
- 200×
- Jan 2026
- Peer median
- 2.0×
Immunome has no meaningful price to sales ratio today: it is not in our data for Oct 23, 2026.
It was last meaningful in Jan 2026, at 200×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 200× | 197× | 200× |
| 2025 | 185× | 54.0× | 187× |
| 2024 | 64.9× | 56.9× | 88.9× |
Against its peers
Companies in Drug Manufacturers - General nearest Immunome's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| IMNMImmunome | n/m |
| HRMYHarmony Biosciences | 2.2× |
| PBHPrestige Consumer Healthcare | 2.0× |
| ANIPANI Pharmaceuticals | 1.7× |
| PAHCPhibro Animal Health | 1.0× |
| NRIXNurix Therapeutics | 3.9× |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 1.9× |
| OMEROmeros | n/m |
| OGNOrganon | 0.6× |
| LQDALiquidia | 8.5× |
| Peer median | 2.0× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Immunome
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.